Patents by Inventor Linhong Li
Linhong Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11963429Abstract: A display module (10) includes: a display panel (12) and a circuit board (14) coupled to the display panel (12). The display panel (12) includes a driving chip (122) and a display unit (124); and the circuit board (14) includes a first filter element (142), wherein the first filter element (142) is coupled to the driving chip (122) and the display unit (124), and a direct current signal output by the driving chip (122) is filtered by the first filter element (142) and then transmitted to the display unit (124). The present disclosure also provides a display apparatus (100).Type: GrantFiled: June 19, 2020Date of Patent: April 16, 2024Assignees: CHENGDU BOE OPTOELECTRONICS TECHNOLOGY CO., LTD., BOE TECHNOLOGY GROUP CO., LTD.Inventors: Yu Wang, Yi Zhang, Tingliang Liu, Tinghua Shang, Huijuan Yang, Yang Zhou, Pengfei Yu, Linhong Han, Hao Zhang, Xiaofeng Jiang, Huijun Li
-
Patent number: 11922838Abstract: A display panel, comprising a first insulating structural layer, a first crack detection line, a second insulating structural layer and a second crack detection line which are sequentially arranged on a substrate, wherein the first crack detection line and the second crack detection line are both located in a peripheral area and are arranged around a display area, one end of the first crack detection line is configured to receive a detection signal, and the other end of the first crack detection line is configured to output a first output signal, and one end of the second crack detection line is configured to receive a detection signal and the other end of the second crack detection line is configured to output a second output signal.Type: GrantFiled: April 13, 2021Date of Patent: March 5, 2024Assignees: Chengdu BOE Optoelectronics Technology Co., Ltd., BOE Technology Group Co., Ltd.Inventors: Yu Wang, Yi Zhang, Tingliang Liu, Chang Luo, Hao Zhang, Huijuan Yang, Tinghua Shang, Yang Zhou, Pengfei Yu, Shun Zhang, Xiaofeng Jiang, Huijun Li, Linhong Han
-
Patent number: 11608511Abstract: Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: contacting the cells with an activating composition; transfecting the cells with a transfection composition comprising (a) donor DNA and (b) a DNA digesting agent; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.Type: GrantFiled: April 13, 2016Date of Patent: March 21, 2023Assignee: MaxCyte, Inc.Inventors: Linhong Li, Madhusudan Peshwa
-
Publication number: 20220265722Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: May 16, 2022Publication date: August 25, 2022Inventors: Linhong LI, Madhusudan PESHWA
-
Patent number: 11331344Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: October 6, 2017Date of Patent: May 17, 2022Assignee: MAXCYTE INC.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Publication number: 20200330519Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: July 2, 2020Publication date: October 22, 2020Inventors: Linhong LI, Madhusudan PESHWA
-
Publication number: 20200318140Abstract: Disclosed herein are methods and compositions for increasing RNA activity in a cell.Type: ApplicationFiled: April 3, 2020Publication date: October 8, 2020Inventors: Siyuan Tan, Dale Ando, Andreas Reik, Linhong Li, Madhusudan V. Peshwa, Haiyan Jiang
-
Publication number: 20200237825Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: April 15, 2020Publication date: July 30, 2020Applicant: Maxcyte, Inc.Inventors: Linhong LI, Madhusudan V. PESHWA
-
Patent number: 10660917Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: May 23, 2017Date of Patent: May 26, 2020Assignee: Maxcyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Publication number: 20190247436Abstract: Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: transfecting the cells by electroporation with a composition comprising (a) a DNA oligo; (b) a DNA digesting agent; and (c) a targeting RNA, wherein the targeting RNA is capped and/or polyadenylated; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.Type: ApplicationFiled: July 21, 2017Publication date: August 15, 2019Inventors: Linhong LI, Cornell ALLEN, Madhusudan PESHWA
-
Publication number: 20190211109Abstract: Provided herein are cell populations transiently expressing a chimeric antigen receptor (CAR) and their use in the chronic treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: January 4, 2019Publication date: July 11, 2019Inventors: Madhusudan V. PESHWA, Linhong LI
-
Publication number: 20180112235Abstract: Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: contacting the cells with an activating composition; transfecting the cells with a transfection composition comprising (a) donor DNA and (b) a DNA digesting agent; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.Type: ApplicationFiled: April 13, 2016Publication date: April 26, 2018Applicant: MaxCyte, Inc.Inventors: Linhong Li, Madhusudan PESHWA
-
Publication number: 20180028567Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: October 6, 2017Publication date: February 1, 2018Applicant: Maxcyte, Inc.Inventors: Linhong LI, Madhusudan V. PESHWA
-
Publication number: 20170258837Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: May 23, 2017Publication date: September 14, 2017Applicant: Maxcyte, Inc.Inventors: Linhong LI, Madhusudan V. PESHWA
-
Patent number: 9669058Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: August 25, 2015Date of Patent: June 6, 2017Assignee: Maxcyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Publication number: 20170029805Abstract: Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: transfecting the cells by electroporation with a composition comprising (a) a DNA oligo and (b) a DNA digesting agent wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.Type: ApplicationFiled: April 13, 2015Publication date: February 2, 2017Inventors: Linhong LI, Madhusudan PESHWA
-
Patent number: 9546350Abstract: The electroporation chamber and its related devices combine the features of an electroporation chamber that acts as a manifold for regulation of sample flow with those of a flow electroporation device to form a regulated flow electroporation device. The invention further comprises a novel regulated flow electroporation chamber that enables conditions in which a sample is uniformly processed in individual fractions or volumes in a fully closed (sterile) system.Type: GrantFiled: August 10, 2010Date of Patent: January 17, 2017Assignee: Maxcyte, Inc.Inventors: Sergey Dzekunov, Nicholas Chopas, Linhong Li
-
Publication number: 20160082045Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: August 25, 2015Publication date: March 24, 2016Inventors: Linhong Li, Madhusudan V. Peshwa
-
Patent number: 9132153Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: May 24, 2013Date of Patent: September 15, 2015Assignee: MaxCyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Publication number: 20140017213Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: May 24, 2013Publication date: January 16, 2014Inventors: Linhong Li, Madhusudan V. Peshwa